MA56508A - Inhibiteur d'egfr pour le traitement du cancer - Google Patents

Inhibiteur d'egfr pour le traitement du cancer

Info

Publication number: MA56508A
Authority: MA; Morocco
Prior art keywords: cancer; treatment; egfr inhibitor; egfr; inhibitor
Prior art date: 2019-06-21

Application number

MA056508A

Other languages

English (en)

Other versions

MA56508B1 (fr

Inventor

Cosimo Dolente

Annick Goergler

David Hewings

Georg Jaeschke

Bernd Kuhn

Yvonne Alice Nagel

Sander Ulrike Obst

Antonio Ricci

Daniel Rueher

Sandra Steiner

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-06-21

Filing date

2020-06-19

Publication date

2022-04-27

2020-06-19 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2022-04-27 Publication of MA56508A publication Critical patent/MA56508A/fr

2023-11-30 Publication of MA56508B1 publication Critical patent/MA56508B1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MA56508A 2019-06-21 2020-06-19 Inhibiteur de l'egfr pour le traitement du cancer MA56508B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP19181754		2019-06-21
PCT/EP2020/067076 WO2020254562A1 (fr)	2019-06-21	2020-06-19	Inhibiteur d'egfr pour le traitement du cancer

Publications (2)

Publication Number	Publication Date
MA56508A true MA56508A (fr)	2022-04-27
MA56508B1 MA56508B1 (fr)	2023-11-30

Family

ID=67139601

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA56508A MA56508B1 (fr)	2019-06-21	2020-06-19	Inhibiteur de l'egfr pour le traitement du cancer

Country Status (28)

Country	Link
US (4)	US20220315593A1 (fr)
EP (4)	EP3986895B1 (fr)
JP (4)	JP7530391B2 (fr)
KR (1)	KR20220024105A (fr)
CN (4)	CN113966335B (fr)
AR (4)	AR119208A1 (fr)
AU (1)	AU2020295703A1 (fr)
BR (1)	BR112021025445B1 (fr)
CA (1)	CA3140485A1 (fr)
CL (1)	CL2021003408A1 (fr)
CO (1)	CO2021017173A2 (fr)
CR (1)	CR20210624A (fr)
DK (1)	DK3986897T3 (fr)
ES (1)	ES2961187T3 (fr)
FI (1)	FI3986897T3 (fr)
HR (1)	HRP20231276T1 (fr)
HU (1)	HUE063676T2 (fr)
IL (1)	IL288522B1 (fr)
LT (1)	LT3986897T (fr)
MA (1)	MA56508B1 (fr)
MX (1)	MX2021015464A (fr)
PE (1)	PE20220576A1 (fr)
PL (1)	PL3986897T3 (fr)
PT (1)	PT3986897T (fr)
RS (1)	RS64720B1 (fr)
SI (1)	SI3986897T1 (fr)
TW (4)	TW202115071A (fr)
WO (4)	WO2020254565A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3139171A1 (fr)	2019-06-21	2020-12-24	F. Hoffmann-La Roche Ag	Nouveaux inhibiteurs d'egfr
AR119208A1 (es)	2019-06-21	2021-12-01	Hoffmann La Roche	DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
AU2023269227A1 (en) *	2022-05-13	2024-10-03	F. Hoffmann-La Roche Ag	New indazole derivatives
AU2023268579A1 (en) *	2022-05-13	2024-09-19	F. Hoffmann-La Roche Ag	Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer
WO2024206858A1 (fr)	2023-03-30	2024-10-03	Revolution Medicines, Inc.	Compositions pour induire une hydrolyse de ras gtp et leurs utilisations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0508715D0 (en) *	2005-04-29	2005-06-08	Astrazeneca Ab	Chemical compounds
CN101273033A (zh) *	2005-09-20	2008-09-24	阿斯利康(瑞典)有限公司	作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
EP2307365B1 (fr)	2008-06-25	2013-03-27	Merck Sharp & Dohme Corp.	Synthèse et utilisation d agents antibactériens hétérocycliques
US8420661B2 (en)	2010-04-13	2013-04-16	Hoffmann-La Roche Inc.	Arylethynyl derivatives
WO2015095807A1 (fr) *	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Traitements du cancer au moyen de combinaisons d'inhibiteurs de l'egfr et de l'erk
WO2016000615A1 (fr) *	2014-07-02	2016-01-07	Sunshine Lake Pharma Co., Ltd.	Composés hétéroaryles et leurs applications pharmaceutiques
WO2016077375A1 (fr) *	2014-11-10	2016-05-19	Genentech, Inc.	Inhibiteurs de bromodomaines et leurs utilisations
CN113149885A (zh)	2015-05-14	2021-07-23	威斯塔解剖学和生物学研究所	Ebna1抑制剂和使用其的方法
TW201834651A (zh) *	2016-12-22	2018-10-01	瑞士商赫孚孟拉羅股份公司	化合物
WO2018220149A1 (fr) *	2017-06-02	2018-12-06	F. Hoffmann-La Roche Ag	Composés
WO2019046668A1 (fr) *	2017-08-31	2019-03-07	Kezar Life Sciences	Thiazoles à substitution amide utilisés en tant qu'inhibiteurs de la sécrétine protéique
MX2020014085A (es)	2018-06-29	2021-03-09	Hoffmann La Roche	Compuestos.
CN113993589A (zh)	2019-06-21	2022-01-28	豪夫迈·罗氏有限公司	新egfr抑制剂
CA3139171A1 (fr)	2019-06-21	2020-12-24	F. Hoffmann-La Roche Ag	Nouveaux inhibiteurs d'egfr
AR119208A1 (es)	2019-06-21	2021-12-01	Hoffmann La Roche	DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

2020
- 2020-06-19 AR ARP200101747A patent/AR119208A1/es unknown
- 2020-06-19 AU AU2020295703A patent/AU2020295703A1/en active Pending
- 2020-06-19 AR ARP200101745A patent/AR119206A1/es unknown
- 2020-06-19 DK DK20734871.5T patent/DK3986897T3/da active
- 2020-06-19 EP EP20734160.3A patent/EP3986895B1/fr active Active
- 2020-06-19 LT LTEPPCT/EP2020/067076T patent/LT3986897T/lt unknown
- 2020-06-19 MX MX2021015464A patent/MX2021015464A/es unknown
- 2020-06-19 AR ARP200101748A patent/AR119209A1/es unknown
- 2020-06-19 WO PCT/EP2020/067082 patent/WO2020254565A1/fr active Application Filing
- 2020-06-19 WO PCT/EP2020/067076 patent/WO2020254562A1/fr active Application Filing
- 2020-06-19 CR CR20210624A patent/CR20210624A/es unknown
- 2020-06-19 JP JP2021576032A patent/JP7530391B2/ja active Active
- 2020-06-19 TW TW109120781A patent/TW202115071A/zh unknown
- 2020-06-19 PE PE2021002089A patent/PE20220576A1/es unknown
- 2020-06-19 RS RS20230942A patent/RS64720B1/sr unknown
- 2020-06-19 MA MA56508A patent/MA56508B1/fr unknown
- 2020-06-19 JP JP2021576020A patent/JP7550799B2/ja active Active
- 2020-06-19 FI FIEP20734871.5T patent/FI3986897T3/fi active
- 2020-06-19 EP EP20734348.4A patent/EP3986896B1/fr active Active
- 2020-06-19 US US17/620,240 patent/US20220315593A1/en active Pending
- 2020-06-19 AR ARP200101749A patent/AR119210A1/es unknown
- 2020-06-19 EP EP20734871.5A patent/EP3986897B1/fr active Active
- 2020-06-19 CA CA3140485A patent/CA3140485A1/fr active Pending
- 2020-06-19 WO PCT/EP2020/067086 patent/WO2020254568A1/fr active Application Filing
- 2020-06-19 HU HUE20734871A patent/HUE063676T2/hu unknown
- 2020-06-19 ES ES20734871T patent/ES2961187T3/es active Active
- 2020-06-19 JP JP2021576031A patent/JP7550800B2/ja active Active
- 2020-06-19 EP EP20734872.3A patent/EP3986898B1/fr active Active
- 2020-06-19 US US17/620,242 patent/US20230054473A1/en active Pending
- 2020-06-19 CN CN202080043708.9A patent/CN113966335B/zh active Active
- 2020-06-19 TW TW109120782A patent/TW202115053A/zh unknown
- 2020-06-19 CN CN202080044300.3A patent/CN114008049B/zh active Active
- 2020-06-19 CN CN202080045269.5A patent/CN113993873B/zh active Active
- 2020-06-19 KR KR1020217041612A patent/KR20220024105A/ko unknown
- 2020-06-19 HR HRP20231276TT patent/HRP20231276T1/hr unknown
- 2020-06-19 PL PL20734871.5T patent/PL3986897T3/pl unknown
- 2020-06-19 US US17/620,239 patent/US20220315592A1/en active Pending
- 2020-06-19 IL IL288522A patent/IL288522B1/en unknown
- 2020-06-19 BR BR112021025445-5A patent/BR112021025445B1/pt active IP Right Grant
- 2020-06-19 WO PCT/EP2020/067093 patent/WO2020254572A1/fr active Application Filing
- 2020-06-19 TW TW109120821A patent/TW202115074A/zh unknown
- 2020-06-19 JP JP2021575205A patent/JP7550798B2/ja active Active
- 2020-06-19 TW TW109120783A patent/TW202115072A/zh unknown
- 2020-06-19 PT PT207348715T patent/PT3986897T/pt unknown
- 2020-06-19 SI SI202030292T patent/SI3986897T1/sl unknown
- 2020-06-19 CN CN202080044011.3A patent/CN113993872B/zh active Active
2021
- 2021-12-15 CO CONC2021/0017173A patent/CO2021017173A2/es unknown
- 2021-12-20 CL CL2021003408A patent/CL2021003408A1/es unknown
- 2021-12-21 US US17/558,053 patent/US20220135571A1/en active Pending

Also Published As

Publication number	Publication date
EP3986897A1 (fr)	2022-04-27
JP7550799B2 (ja)	2024-09-13
CO2021017173A2 (es)	2022-01-17
CN113966335B (zh)	2024-08-02
DK3986897T3 (da)	2023-10-30
LT3986897T (lt)	2023-11-10
CL2021003408A1 (es)	2022-10-14
CN113966335A (zh)	2022-01-21
CN113993872B (zh)	2024-09-24
HUE063676T2 (hu)	2024-01-28
FI3986897T3 (fi)	2023-10-20
CN113993873A (zh)	2022-01-28
CN114008049B (zh)	2024-07-05
PE20220576A1 (es)	2022-04-20
JP2022537191A (ja)	2022-08-24
PL3986897T3 (pl)	2024-01-22
TW202115072A (zh)	2021-04-16
US20220315592A1 (en)	2022-10-06
SI3986897T1 (sl)	2023-12-29
TW202115053A (zh)	2021-04-16
US20230054473A1 (en)	2023-02-23
JP2022538403A (ja)	2022-09-02
TW202115071A (zh)	2021-04-16
BR112021025445B1 (pt)	2024-02-27
WO2020254568A1 (fr)	2020-12-24
EP3986895B1 (fr)	2023-03-15
PT3986897T (pt)	2023-10-23
WO2020254572A1 (fr)	2020-12-24
MX2021015464A (es)	2022-01-24
WO2020254565A1 (fr)	2020-12-24
CN113993873B (zh)	2024-08-02
JP7550798B2 (ja)	2024-09-13
IL288522B1 (en)	2024-10-01
AU2020295703A1 (en)	2022-01-06
US20220135571A1 (en)	2022-05-05
AR119209A1 (es)	2021-12-01
CN113993872A (zh)	2022-01-28
US20220315593A1 (en)	2022-10-06
WO2020254562A1 (fr)	2020-12-24
EP3986897B1 (fr)	2023-08-30
IL288522A (en)	2022-01-01
EP3986898A1 (fr)	2022-04-27
HRP20231276T1 (hr)	2024-02-02
RS64720B1 (sr)	2023-11-30
CR20210624A (es)	2022-02-14
EP3986895A1 (fr)	2022-04-27
EP3986896B1 (fr)	2023-03-15
JP2022538055A (ja)	2022-08-31
JP7550800B2 (ja)	2024-09-13
MA56508B1 (fr)	2023-11-30
CN114008049A (zh)	2022-02-01
EP3986898B1 (fr)	2023-03-15
TW202115074A (zh)	2021-04-16
JP7530391B2 (ja)	2024-08-07
EP3986896A1 (fr)	2022-04-27
BR112021025445A2 (pt)	2022-02-01
AR119206A1 (es)	2021-12-01
AR119208A1 (es)	2021-12-01
JP2022537769A (ja)	2022-08-29
CA3140485A1 (fr)	2020-12-24
ES2961187T3 (es)	2024-03-08
AR119210A1 (es)	2021-12-01
KR20220024105A (ko)	2022-03-03

Publication	Publication Date	Title
MA55959A (fr)	2022-03-23	Dosage d'inhibiteur de kras pour le traitement de cancers
MA52780A (fr)	2021-04-14	Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr)	2021-03-17	Inhibiteurs de kras g12c pour le traitement du cancer
MA56508A (fr)	2022-04-27	Inhibiteur d'egfr pour le traitement du cancer
MA52232A (fr)	2021-02-17	Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA49144A (fr)	2020-03-25	Polythérapies pour le traitement du cancer
MA54609A (fr)	2022-04-06	Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54608A (fr)	2022-04-06	Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA45037A (fr)	2019-03-27	Polythérapie à base d'arnm pour le traitement du cancer
MA50409A (fr)	2020-08-26	Polythérapies pour le traitement du cancer
MA51418A (fr)	2020-11-04	Inhibiteurs de glycolate oxydase pour le traitement de maladies
MA51139A (fr)	2020-10-21	Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA48637A (fr)	2021-03-17	Polythérapies pour le traitement du cancer
MA52657A (fr)	2021-02-17	Anticorps spécifiques d'axl pour le traitement du cancer
MA55560A (fr)	2022-02-09	Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
MA43170A (fr)	2018-09-12	Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MA51613A (fr)	2020-11-25	Polythérapie pour le traitement ou la prévention du cancer
MA50943A (fr)	2020-10-07	Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
MA53873A (fr)	2022-01-19	Compositions et procédés pour le traitement de la presbytie
MA55218A (fr)	2022-01-12	Eskétamine pour le traitement de la dépression
MA55093A (fr)	2022-01-05	Méthodes et compositions pour le traitement du cancer
MA55490A (fr)	2022-02-09	Mutéine de lipocaline pour le traitement de l'asthme
MA55982A (fr)	2022-03-23	Composition pharmaceutique pour le traitement de tumeurs
MA45973A (fr)	2019-06-26	Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA52499A (fr)	2021-04-14	Associations pour le traitement du cancer